Literature DB >> 11464277

PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme.

A K Struss1, B F Romeike, A Munnia, W Nastainczyk, W I Steudel, J König, H Ohgaki, W Feiden, U Fischer, E Meese.   

Abstract

Glioblastoma multiforme (GBM), a malignant astrocytic tumour, represents the most frequent tumour of the human brain. Nevertheless, its molecular pathology is not well understood. We utilized the immune system, which contributes to cancer protection, to help identify new GBM-related genes. By screening a human GBM cDNA library with autologous patient serum (SEREX-approach), we isolated a gene termed PHF3 (PHD finger protein 3). The gene product of PHF3 is immunogenic in GBM as tested in an allogenic patient serum screening demonstrating antibodies in 24 of 39 (61.53%) sera, whereas none of the 14 healthy persons had antibodies against PHF3. While previous SEREX studies revealed allogenic antibody responses up to 40%, our results for PHF3 represent the highest reported rate for a specific antibody response. We show that GBM patients with an antibody response against PHF3 show significant better survival than patients without PHF3-specific antibodies. Because the amino acid sequence of PHF3 contains a PHD finger (also termed LAP motif), a TFIIS homology, a proline rich region and nuclear localization signals, it supposedly functions as a transcription factor. A polyclonal antibody generated against PHF3 shows nuclear expression in most investigated formalin-fixed, paraffin embedded tissues. In GBM, PHF3 expression is concentrated in cells surrounding necroses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11464277     DOI: 10.1038/sj.onc.1204552

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival.

Authors:  Isaac Yang; Tarik Tihan; Seunggu J Han; Margaret R Wrensch; John Wiencke; Michael E Sughrue; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2010-08-19       Impact factor: 1.961

2.  Improving seroreactivity-based detection of glioma.

Authors:  Nicole Ludwig; Andreas Keller; Sabrina Heisel; Petra Leidinger; Veronika Klein; Stefanie Rheinheimer; Claudia U Andres; Bernhard Stephan; Wolf-Ingo Steudel; Norbert M Graf; Bernhard Burgeth; Joachim Weickert; Hans-Peter Lenhof; Eckart Meese
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

3.  Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selection.

Authors:  M E Olszko; J E Adair; I Linde; D T Rae; P Trobridge; J D Hocum; D J Rawlings; H-P Kiem; G D Trobridge
Journal:  Gene Ther       Date:  2015-03-19       Impact factor: 5.250

4.  Transcriptional characterization of immunological infiltrates and their relation with glioblastoma patients overall survival.

Authors:  Mariana Brutschin Pereira; Luciana Rodrigues Carvalho Barros; Paula A Bracco; Alvaro Vigo; Mariana Boroni; Martín Hernán Bonamino; Guido Lenz
Journal:  Oncoimmunology       Date:  2018-02-12       Impact factor: 8.110

5.  Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.

Authors:  Madhumita Chatterjee; Saroj Mohapatra; Alexei Ionan; Gagandeep Bawa; Rouba Ali-Fehmi; Xiaoju Wang; James Nowak; Bin Ye; Fatimah A Nahhas; Karen Lu; Steven S Witkin; David Fishman; Adnan Munkarah; Robert Morris; Nancy K Levin; Natalie N Shirley; Gerard Tromp; Judith Abrams; Sorin Draghici; Michael A Tainsky
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

Review 6.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma.

Authors:  Gavin P Dunn; Ian F Dunn; William T Curry
Journal:  Cancer Immun       Date:  2007-08-13

7.  Autologous adjuvant linked fibroblasts induce anti-glioma immunity: implications for development of a glioma vaccine.

Authors:  Andrew T Parsa; John I Miller; Arnold E Eggers; Alfred T Ogden; Richard C Anderson; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

8.  Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas.

Authors:  Tomoo Matsutani; Takaki Hiwasa; Masaki Takiguchi; Takashi Oide; Mitoshi Kunimatsu; Naokatsu Saeki; Yasuo Iwadate
Journal:  J Exp Clin Cancer Res       Date:  2012-10-11

9.  SPOC: a widely distributed domain associated with cancer, apoptosis and transcription.

Authors:  Luis Sánchez-Pulido; Ana M Rojas; Karel H van Wely; Carlos Martinez-A; Alfonso Valencia
Journal:  BMC Bioinformatics       Date:  2004-07-07       Impact factor: 3.169

10.  Increased seroreactivity to glioma-expressed antigen 2 in brain tumor patients under radiation.

Authors:  Sabrina M Heisel; Ralf Ketter; Andreas Keller; Veronika Klein; Christian P Pallasch; Hans-Peter Lenhof; Eckart Meese
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.